reported a patient with multiline-resistant refractory PCNSL who received decitabine-primed tandem CD19/CD22 CAR-T therapy with PD-1 and BTK Inhibitors maintenance and eventually maintained complete remission (CR) for a 35-month follow-up period (83). Here, CD22 is linked to primary central nervous system lymphoma.